Aiforia secures €20m EU financing for AI cancer detection
The European Investment Bank has signed a €20m venture debt agreement with Finnish life-science company Aiforia, backing further development of its AI platform for detecting cancer in tissue samples. The financing is supported under the EU’s InvestEU programme.
Text by Martti Asikainen, 13.8.2026 | Photo by Aiforia (edited by FAIR)
The European Investment Bank (EIB) has signed a €20m venture debt financing agreement with Aiforia, a Helsinki-based life-science technology company. The funding is supported under the European Commission’s InvestEU programme.
The financing will support further development of Aiforia’s AI-powered platform, which helps pathologists analyse digital tissue samples, particularly for detecting tumours. The software examines ultra-high-resolution images of biopsy samples to identify cancer cells with speed and precision.
Aiforia said it plans to use the funding to accelerate product development on existing and new image analysis tools, and to expand its commercial operations internationally.
How the deal is structured
The deal fits into a broader EU effort to keep promising health technology companies from being acquired by, or dependent on, non-European players.
Karl Nehammer, an EIB vice-president, said Aiforia’s work strengthens European competitiveness while giving the company “the opportunity to succeed on the global stage” — language that reflects the EIB’s stated priority of funding firms it considers strategically important to European tech sovereignty, alongside similar recent EIB deals in AI and life sciences.
For Aiforia, the financing arrives at a point where the company is trying to convert years of regulatory groundwork into commercial traction. Chief executive Jukka Tapaninen said the funding would strengthen the company’s financial position and support its strategy, enabling it to accelerate product development and expand international commercial operations.
That expansion push follows a period in which Aiforia secured CE-IVD clinical marking for cancer-detection models and won a UK contract to supply AI tools to NHS pathology departments — evidence, the company argues, that its technology is moving from research use into routine clinical diagnosis.
Head of the European Commission’s representation in Finland, Elina Laurinen, welcomed the financing as support for the country’s high-tech clusters, tying the deal to Finland’s wider positioning as a base for European AI and life-science firms.
About Aiforia
Aiforia was founded in Helsinki in 2013, originally under the name Fimmic, by Kari Pitkanen, Johan Lundin and Mikael Lundin. Tapaninen joined in 2015 as the company began applying deep learning to pathology image analysis; it rebranded its platform as Aiforia Cloud in 2018.
The company went public in December 2021 on Nasdaq’s First North Growth Market in Helsinki, raising around €30m. That followed roughly €28m in earlier venture funding, including a €17.5m Series B round in September 2021 led by an entity of Epredia, a subsidiary of Japan’s PHC Holdings.
Aiforia has also received EU support before this latest deal, including a €2.1m Horizon 2020 grant in 2019 and a €7.3m funding decision from Business Finland in 2023.
Aiforia’s software is used across three products — Aiforia Create, Aiforia On-Demand and Aiforia Cloud — and the company holds CE-IVD clinical marking for a number of cancer-detection AI models, including for lung and breast cancer. It has supplied AI tools to NHS pathology trusts in the UK, including a PD-L1 lung cancer model adopted under the PathLAKE Plus research consortium. The company operates in a competitive field alongside firms including PathAI, Paige and Denmark’s Visiopharm.
